Formulation studies and in vivo evaluation of a flurbiprofen-hydroxypropyl β-cyclodextrin system

Pharmaceutical Development and Technology

Volumn 10, Issue 1, 2005, Pages 105-114

  Govindarajan, Ramprakash ^a,b   Nagarsenker, Mangal S ^a  

^a BOMBAY COLLEGE OF PHARMACY   (India)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bioavailability; Flurbiprofen; Formulation; Hydroxypropyl cyclodextrin; Solid dispersions; Ulcerogenicity

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CARBOXYMETHYLCELLULOSE; EXCIPIENT; FLURBIPROFEN; PHOSPHATE; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPSULE FILLING; CONTROLLED STUDY; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG FORMULATION; DRUG MANUFACTURE; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; EVAPORATION; HYDROPHILICITY; IN VIVO STUDY; NONHUMAN; PH MEASUREMENT; POWDER; PRIORITY JOURNAL; RAT; SOLID STATE; STOMACH JUICE; TABLET FORMULATION; ULCEROGENESIS;

ANIMALS; BETA-CYCLODEXTRINS; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DRUG EVALUATION, PRECLINICAL; EDEMA; FLURBIPROFEN; HUMANS; MALE; RATS; RATS, WISTAR;

EID: 14644390340     PISSN: 10837450     EISSN: None     Source Type: Journal    
DOI: 10.1081/PDT-200049687     Document Type: Article

References (16)

1. Tokumura, T.; Tsushima, Y.; Kayano, M.; Machida, Y.; Nagai, T. Enhancement of bioavailability of cinnarizine from its beta cyclodextrin complex on oral administration with dl-phenylalanine as a competing agent. J. Pharm. Sci. 1985, 74, 496-497.
2. Frijlink, H.W.; Franssen, E.J.F.; Eissens, A.C.; Oosting, R.; Lerk, C.F.; Meijer, D.K.F. The effect of cyclodextrins on the disposition of intravenously injected drug in rat. Pharm. Res. 1991, 8 (3), 380-384.
3. Junquera, E.; Martin-Pastor, M.; Aicart, E. Molecular encapsulation of FPN and/or ibuprofen by hydroxypropyl β-cyclodextrin in aqueous solution. Potentiometric and molecular modeling studies. J. Org. Chem. 1998, 63 (13), 4349-4358.
4. Kagkadis, K.A.; Rekkas, D.M.; Dallas, P.P.; Choulis, N.H. Freeze-dried injectable form of FPN: development and optimization using response surface methodology. Int. J. Pharm. 1998, 161, 87-94.
5. Govindarajan, R.; Nagarsenker, M.S. Influence of preparation methodology on solid-state properties of an acidic drug-cyclodextrin system. J. Pharm. Pharmacol. 2004, 56, 725-733.
6. Hirayama, M.; Moriya, F.; Fukunaga, K.; Ootani, T. FPN-Hydroxypropyl β-Cyclodextrin Inclusion Compound and Its Use as Anti-Inflammatory and Analgesic Agent. Japanese Patent 03005438 A2, 1991.
7. Blanco, J.; Vila-Jato, J.L.; Otero, F.; Anguiano, S. Influence of method of preparation on inclusion complexes of naproxen with different cyclodextrins. Drug. Dev. Ind. Pharm. 1991, 17, 943-957.
8. Higuchi, T.; Connors, K.A. Phase solubility techniques. Adv. Anal. Chem. Instrum. 1965, 4, 117-212.
9. United States Pharmacopeia 27/National Formulary 22; United States Pharmacopeial Convention, Inc.: Rockville, MD, 2004; pp. 834-835, 2303-2304.
10. Chiou, W.L.; Riegelman, S. Pharmaceutical application of solid dispersion systems. J. Pharm. Sci. 1971, 60, 1281-1302.
11. Vogel, H.G.; Vogel, W.H. Drug Discovery and Evaluation: Pharmacological Assays; Springer-Verlag: Berlin, Heidelberg, 1997; 106-407.
12. Nambu, N.; Kikuchi, K.; Kikuchi, T.; Takahashi, Y.; Ueda, H.; Nagai, T. Influence of inclusion of non steroidal anti-inflammatory drugs with β-cyclodextrin on the irritation to stomach of rats upon oral administration. Chem. Pharm. Bull. 1978, 26, 3609-3612.
13. Szejtli, J. Cyclodextrins in pharmaceuticals. In Cyclodextrin Technology; Kluwer Academic Publishers: Dordrecht, 1988; 186-299.
14. Insel, P.A. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in treatment of gout. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th Ed.; Hardman, J.G., Limbird, L.E., Eds.; McGraw Hill: New York, 1996; 618.
15. Fielden, K.E.; Newton, J.M.; O'Brien, P.; Rowe, R.C. Thermal studies on the interaction of water and microcrystalline cellulose. J. Pharm. Pharmacol. 1988, 40, 674-678.
16. Bryan, J.W.; McCallister, D.J. Matrix forming capabilities of three calcium diluents. Drug Dev. Ind. Pharm. 1992, 18, 2029-2047.